cygb1 Antibody

What is cytoglobin and why are CYGB antibodies important for research?

Cytoglobin (CYGB) is a 190-amino acid hemoprotein of the globin family with a calculated molecular weight of 21 kDa, though it often appears at 27-29 kDa in immunoblotting. CYGB functions in oxygen storage/transfer, nitric oxide dioxygenase activity, and protection against oxidative stress .

CYGB antibodies are critical research tools because they enable:

• Detection and quantification of CYGB in various tissues and cell types

• Investigation of CYGB's roles in physiological and pathological processes

• Exploration of CYGB's potential as a diagnostic marker or therapeutic target

Unlike other globins, CYGB is uniquely expressed in fibroblasts and specific neuronal populations, making antibodies against it valuable for studying diverse tissues including liver, heart, and brain .

What applications are CYGB antibodies validated for?

CYGB antibodies have been validated for multiple experimental applications:

Methodological consideration: Always validate antibody specificity using appropriate positive and negative controls. For instance, tissues from CYGB knockout mice serve as excellent negative controls for specificity verification .

How do I select the appropriate CYGB antibody for my research?

Selection should be based on:

• Target species reactivity: Confirm reactivity with your experimental model (human, mouse, rat). Note that human CYGB shares 95.3% and 93.7% amino acid sequence identity with mouse and rat CYGB, respectively .

• Antibody format:

  • Monoclonal: Offers high specificity for a single epitope (ideal for detecting specific isoforms)

  • Polyclonal: Recognizes multiple epitopes (better for detecting proteins in denatured conditions)

• Target region: Various antibodies target different regions (AA 1-190, AA 87-132) . Consider whether your research question requires targeting a specific domain.

• Validation data: Review published literature and supplier data to ensure the antibody has been rigorously validated for your application.

• Conjugation: For direct detection methods, consider pre-conjugated antibodies (biotin, fluorescent dyes) .

How should I validate CYGB antibody specificity in my experimental system?

Comprehensive validation requires multiple approaches:

• Positive and negative controls:

  • CYGB knockout/knockdown samples (ideal negative control)

  • CYGB-overexpressing samples (ideal positive control)

  • Multi-tissue panel (CYGB is highly expressed in fibroblasts and specific neurons)

• Validation methods:

  • Western blot: Confirm a single band at the expected molecular weight (27-29 kDa)

  • Immunoprecipitation followed by mass spectrometry to confirm target identity

  • Peptide competition assay to demonstrate binding specificity

  • Tissue panel comparison with known CYGB expression patterns

• Cross-reactivity testing: Verify the antibody doesn't cross-react with other globin family members (hemoglobin, myoglobin, neuroglobin) .

Methodological note: Quantitative immunoblotting comparing the levels of each globin to purified protein standards has shown that CYGB is the most abundant globin in aortic smooth muscle cells (~5 μM), with myoglobin levels over 40-fold lower and hemoglobin-α more than 200-fold lower .

What are the optimal fixation and antigen retrieval methods for CYGB immunohistochemistry?

Optimization is essential for accurate CYGB detection in tissue sections:

• Fixation methods:

  • 4% paraformaldehyde (most common for IF/IHC)

  • 10% neutral-buffered formalin (for paraffin embedding)

  • Methanol/acetone (alternative for some applications)

• Antigen retrieval recommendations:

  • Heat-induced epitope retrieval using TE buffer pH 9.0 (preferred method)

  • Alternative: Citrate buffer pH 6.0

  • Timing: 20 minutes at 95-100°C is typically sufficient

• Blocking conditions:

  • 5-10% normal serum from the same species as the secondary antibody

  • 1-3% BSA in PBS to reduce non-specific binding

  • Include 0.1-0.3% Triton X-100 for intracellular targets

Methodological insight: CYGB shows distinct localization patterns in different cell types. In non-neuronal cells (fibroblasts), CYGB staining is cytoplasmic, whereas in neurons, both cytoplasmic and nuclear staining are observed . This differential localization may require adjusted permeabilization protocols.

What controls are essential when using CYGB antibodies in quantitative applications?

For accurate quantification:

• Antibody titration curve to determine optimal concentration in linear detection range

• Essential controls:

  • Technical replicates (at least triplicates)

  • Biological replicates (at least three independent samples)

  • Positive control (tissue/cells known to express CYGB)

  • Negative control (CYGB-knockout tissue or isotype control)

  • Loading control (for western blots)

  • Standard curve (for quantitative approaches)

• For western blotting:

  • Use purified recombinant CYGB protein standards of known concentrations

  • Implement normalization with validated housekeeping proteins

  • Consider multiplex detection approaches to control for loading variability

• For immunohistochemistry:

  • Include unstained tissue sections

  • Include secondary-only controls

  • Use isotype controls at equivalent concentrations

How can CYGB antibodies be utilized to investigate CYGB's role in cancer biology?

CYGB has been implicated as a potential tumor suppressor, making it an important cancer research target :

• Experimental approaches:

  • Tissue microarray analysis of CYGB expression across cancer types and stages

  • Correlation of CYGB levels with clinical outcomes and tumor characteristics

  • Co-immunoprecipitation to identify CYGB-interacting proteins in cancer cells

  • ChIP assays to investigate epigenetic regulation of CYGB in tumors

• Research findings to build upon:

  • CYGB overexpression dysregulates multiple cancer-associated genes

  • CYGB affects mTORC1 and AKT/mTOR signaling pathways, which are frequently overactivated in tumors

  • CYGB overexpression downregulates epithelial-mesenchymal transition (EMT) pathways

  • CYGB exhibits anti-inflammatory potential by downregulating key inflammasome-associated genes

• Experimental design consideration:

  • Compare CYGB expression in paired tumor/normal tissues

  • Evaluate CYGB in the context of hypoxia (common in tumors)

  • Assess correlation with oxidative stress markers

Recent research demonstrated that ectopic expression of CYGB in A375 melanoma cells affected multiple pathways implicated in cancer progression, suggesting its potential as a therapeutic target .

What strategies can overcome technical challenges when detecting low levels of CYGB in tissue samples?

For samples with low CYGB expression:

• Signal amplification methods:

  • Tyramide signal amplification (TSA) for IHC/IF (increases sensitivity 10-100 fold)

  • Polymer-based detection systems

  • Biotin-streptavidin amplification systems

  • Enhanced chemiluminescence substrates for western blotting

• Sample preparation optimization:

  • Enrichment through subcellular fractionation

  • Immunoprecipitation before western blotting

  • Extended exposure times with low-noise detection systems

  • Concentration of protein samples using TCA precipitation

• Antibody optimization:

  • Try both monoclonal and polyclonal antibodies (different epitope recognition)

  • Consider antibodies against different regions of CYGB

  • Sequential incubation with multiple antibodies

  • Combine multiple detection methods for validation

Methodological insight: In studies of CYGB in the auditory brainstem, researchers have successfully quantified low-abundance CYGB-expressing neurons (only 6-10% of total neurons) using careful optimization of antibody concentration and signal amplification techniques .

How can CYGB antibodies be used to investigate the relationship between CYGB and nitric oxide signaling?

CYGB functions as a nitric oxide dioxygenase (NOD), making this relationship particularly important :

• Experimental approaches:

  • Co-immunostaining of CYGB with nNOS (neuronal nitric oxide synthase)

  • Proximity ligation assays to detect CYGB-NOS interactions

  • Immunoprecipitation followed by activity assays

  • FRET-based approaches to study real-time interactions

• Key findings to build upon:

  • CYGB is the most abundant globin in aortic smooth muscle cells (~5 μM)

  • CYGB colocalizes with nNOS in neurons of the superior olivary complex

  • CYGB regulates blood pressure and vascular tone through NO metabolism

  • In cardiac progenitor cells, CYGB increases iNOS-dependent NO production

• Methodological considerations:

  • Use both acute and chronic models of NO modulation

  • Consider the subcellular localization of CYGB and NOS enzymes

  • Combine antibody-based methods with functional NO measurements

Research has shown that CYGB frequently co-localizes with neuronal nitric oxide synthase (nNOS) in neurons, suggesting functional interaction between these proteins in regulating NO metabolism and oxygen homeostasis .

Why might I observe CYGB at different molecular weights in western blot analysis?

Multiple molecular weight bands can occur for several reasons:

• Post-translational modifications:

  • Phosphorylation

  • Glycosylation

  • Ubiquitination

• Technical explanations:

  • Calculated MW is 21 kDa, but observed MW is often 27-29 kDa

  • Partial proteolysis during sample preparation

  • Alternative splicing variants

  • Dimerization or complex formation

• Validation approaches:

  • Deglycosylation/dephosphorylation treatment

  • Mass spectrometry analysis of observed bands

  • Use of multiple antibodies targeting different epitopes

  • Comparison with recombinant protein standards

The discrepancy between calculated (21 kDa) and observed (27-29 kDa) molecular weights has been consistently reported in multiple studies and may reflect tissue-specific post-translational modifications .

How do I resolve contradictory findings when comparing CYGB expression data from different antibodies?

This common challenge requires systematic investigation:

• Source of discrepancies:

  • Epitope differences (different antibodies target different regions)

  • Cross-reactivity with related proteins

  • Detection of different isoforms or post-translationally modified forms

  • Technical variables (fixation, antigen retrieval, detection methods)

• Resolution strategies:

  • Compare epitope sequences targeted by each antibody

  • Validate with genetic approaches (knockdown, knockout, overexpression)

  • Use orthogonal detection methods (mRNA, mass spectrometry)

  • Perform side-by-side comparison under identical conditions

  • Consult published validation studies for each antibody

• Experimental approach:

  • Test all antibodies on the same samples simultaneously

  • Include appropriate positive and negative controls

  • Document all methodological details meticulously

When investigating CYGB expression in neurons versus fibroblasts, different antibodies may yield varying results due to potential conformational differences in CYGB between these cell types .

What are the best practices for quantifying CYGB expression levels in immunohistochemistry?

Accurate quantification requires rigorous methodology:

• Technical considerations:

  • Use digital image analysis software rather than manual scoring

  • Standardize acquisition parameters (exposure, gain, offset)

  • Implement batch processing to minimize session-to-session variation

  • Use consistent thresholding methods

• Quantification approaches:

  • H-score (combines intensity and percentage of positive cells)

  • Average intensity measurement

  • Percentage of positive cells

  • Subcellular localization pattern analysis

• Statistical analysis:

  • Blind scorers to experimental conditions

  • Evaluate multiple fields per sample (minimum 5-10)

  • Use appropriate statistical tests based on data distribution

  • Account for multiple comparisons

• Validation:

  • Correlate IHC findings with western blot data when possible

  • Verify with an independent antibody

  • Consider multiplexed approaches to analyze CYGB in context of other markers

In studies of CYGB in the superior olivary complex, researchers quantified both the total number of CYGB-expressing neurons and their percentage relative to total neuron count, finding significant variation between species (10±1% in rats versus 6±1% in mice) .

How can CYGB antibodies be employed to investigate CYGB's role in oxidative stress protection?

CYGB has been implicated in cellular protection against oxidative stress :

• Experimental approaches:

  • Temporal analysis of CYGB expression during oxidative stress induction

  • Co-immunoprecipitation to identify stress-specific interaction partners

  • ChIP-seq to determine if CYGB acts as a transcriptional regulator under stress

  • Analysis of subcellular redistribution during stress conditions

• Research models:

  • H₂O₂ treatment of cultured cells

  • Ischemia-reperfusion injury models

  • Chronic oxidative stress in disease models

  • Hypoxia/reoxygenation protocols

• Key findings to build upon:

  • CYGB overexpression in cardiac progenitor cells upregulates antioxidant systems like peroxiredoxin-1 and heme oxygenase-1

  • CYGB promotes survival of cells under oxidative stress conditions

  • CYGB modulates expression of anti-apoptotic factors like BCL2, BCL-XL, and MCL1

Research has shown that CYGB functions as a pro-survival factor in human cardiac progenitor cells exposed to oxidative stress, suggesting its potential therapeutic application in ischemic heart disease .

What emerging techniques can enhance the utility of CYGB antibodies in cellular and molecular research?

Several innovative approaches show promise:

• Advanced imaging techniques:

  • Super-resolution microscopy (STORM, PALM) for nanoscale localization

  • Live-cell imaging with CYGB antibody fragments

  • Expansion microscopy for improved spatial resolution

  • Correlative light and electron microscopy

• High-throughput applications:

  • Microfluidic-based single-cell western blotting

  • Mass cytometry (CyTOF) with metal-conjugated CYGB antibodies

  • Spatial transcriptomics combined with CYGB immunostaining

  • Automated tissue cytometry for large-scale analysis

• Functional analysis:

  • CRISPR-based screening with CYGB antibody readouts

  • Intrabodies (intracellular antibodies) to modulate CYGB function

  • Proximity-dependent biotinylation to identify interaction networks

  • Optogenetic regulation combined with antibody detection

These approaches could significantly advance our understanding of CYGB's diverse roles in various cellular contexts and pathological conditions.

How can CYGB antibodies contribute to translational research on potential therapeutics targeting CYGB pathways?

CYGB's diverse functions make it a promising therapeutic target :

• Therapeutic development applications:

  • Screening compounds that modulate CYGB expression or function

  • Evaluating drug effects on CYGB-dependent signaling pathways

  • Monitoring CYGB in patient-derived samples during clinical trials

  • Developing companion diagnostics for CYGB-targeting therapies

• Disease-specific approaches:

  • Cancer: Restore CYGB expression in tumors where it's downregulated

  • Fibrosis: Modulate CYGB in activated fibroblasts

  • Neurodegenerative disorders: Target CYGB's neuroprotective functions

  • Cardiovascular disease: Enhance CYGB's cardioprotective effects

• Methodological considerations:

  • Tissue-specific delivery systems for targeted therapy

  • Combination approaches targeting multiple aspects of CYGB biology

  • Patient stratification based on CYGB expression/function

  • Development of humanized model systems